Previous studies have demonstrated that SPRED2 expression is downregulated in several cancers, including prostate cancer [18], colorectal cancer [19], advanced urothelial carcinoma [20], hepatocellular carcinoma [21], lung adenocarcinoma [22], and BC [23]. Here, SPRED2 is linked to breast cancer.